
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is well positioned by its diversified portfolio, with Keytruda, Gardasil, vaccines, and animal health supporting resilient cash generation, while 53% of 2025 sales came from US human health. The positive outlook is anchored in the company’s ability to defend and expand Keytruda and Gardasil share despite competition, while stronger commercialization of Winrevair and Ohtuvayre could add meaningful revenue upside. Confidence is also reinforced by late-stage pipeline momentum, including positive oncology readouts such as sac-TMT and intismeran, which may help offset Keytruda’s 2028 loss of exclusivity and support a longer growth runway.
Bears say
Merck & Co is facing a tougher fundamental setup as 2027 is expected to be a strategic investment year with elevated R&D and SG&A, while legacy LOE pressures from Bridion, Januvia/Janumet, and Adempas are not being fully offset by Winrevair, Welireg, and Capvaxive. Keytruda remains the core profit engine, but its growth is slowing as the franchise nears peak penetration and approaches the year-end 2028 patent cliff, while international pricing pressure and higher German rebates further trim earnings power. With 3Q26 sales roughly in line excluding one-time items, the outlook remains pipeline-dependent, and the company’s 2027 EPS estimate of $8.55 versus Street $9.23 implies muted growth at a premium 17.1x valuation.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Merck (MRK) Forecast
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares